Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Despite great interest, two randomised controlled trials (RCTs) of cytoreductive nephrectomy in the tyrosine kinase inhibitor setting in metastatic renal cell carcinoma have either closed early (SURTIME) or are recruiting very slowly (CARMENA) after 7 yr. Challenges in RCT delivery in uro-oncologic surgery are many. Multiple steps are needed to ensure strong recruitment to trials addressing important urologic cancer questions. Feasibility/pilot studies are key stepping stones towards successful delivery of surgical RCTs.
Description
Keywords
Antineoplastic Agents, Carcinoma, Renal Cell, Chemotherapy, Adjuvant, Cytoreduction Surgical Procedures, Evidence-Based Medicine, Humans, Kidney Neoplasms, Molecular Targeted Therapy, Nephrectomy, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Treatment Outcome
Journal Title
Eur Urol
Conference Name
Journal ISSN
0302-2838
1873-7560
1873-7560
Volume Title
71
Publisher
Elsevier BV
Publisher DOI
Sponsorship
CARMENA is sponsored by Assistance Publique-Hôpitaux de Paris (APHP). CARMENA-UK was funded by Cancer Research UK and administered by the CRUK Clinical Trials Unit, The Beatson West of Scotland Cancer Centre, Glasgow. SURTIME was sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).